



MNG LABORATORIES  
A LabCorp Company

About Us

Careers

Client Billing

Search



LabCorp

Testing

Programs & Services

Resources

Contact Us

## Our Company

[Home](#) / [About Us](#)

## About MNG Laboratories

MNG Laboratories, a LabCorp Company, is an internationally recognized clinical diagnostic leader specializing in neurogenetic and complex biochemical testing. MNG is committed to a patient-centered testing menu, high-quality diagnostics, and clear and accurate reporting driven by the Genome Manager<sup>®</sup> analysis pipeline. Our team-based approach to data interpretation provides actionable results on the variants that cause or are likely to cause disease. MNG's comprehensive approach to diagnostics is accompanied by a team of customer support and scientific personnel available to answer questions regarding processes, technology, and reports.

With more than 15 years of neurogenetic experience, and powered by a culture of discovery and advancement, MNG Laboratories delivers results that make a difference for patients and their families.



## Company History

### 2019

- > Acquired by Laboratory Corporation of America Holdings on March 1, officially becoming MNG Laboratories, A LabCorp Company

America Holdings on March 1, officially becoming MNG Laboratories, A LabCorp Company

## 2018

- › Launched the MNGenome<sup>®</sup>, whole genome sequencing analysis
- › Launch of MNG Answers<sup>®</sup> programs including no-cost familial variant testing (MNG VIP<sup>®</sup>) and reflex options for negative panels and MNG Exome
- › Introduced MNG STAT testing services for whole exome and whole genome sequencing, with results available in 10-14 days

## 2017

- › Expanded commercial operations to improve overall support to US and International clients
- › Increased pathogenic coverage across the company's next-generation sequencing panel offerings
- › Launched the industry's first commercially available clinical RNA sequencing service
- › Established a Scientific Advisory Board of internationally recognized experts
- › Enhanced the MNG Exome to provide coverage of all expert approved ClinVar pathogenic variants, including those located in intronic or intergenic regions

## 2016

- › CAP Accreditation received
- › Redefined 'comprehensive' by adding copy number, mtDNA testing, and repeat expansion analysis to clinically relevant panels
- › Developed the MNG Genome Manager<sup>®</sup> variant analysis pipeline to improve variant and reporting calls
- › Introduced the MNG Exome family of products, including the MNG Carrier Exome to address unmet needs in the



- > Developed the MNG Genome Manager<sup>®</sup> variant analysis pipeline to improve variant and reporting calls
- > Introduced the MNG Exome family of products, including the MNG Carrier Exome to address unmet needs in the carrier testing market

## 2015

- > Rebranded as MNG Laboratories<sup>™</sup> and began a relationship with a private equity partner to invest in equipment and infrastructure to advance the company's growth plan

## 2013

- > Improved diagnostic capabilities by offering repeat expansion testing for selected disorders

## 2012

- > Introduced MNG's first next-generation sequencing panels

## 2010

- > Medical Neurogenetics, LLC grew national and international institutional referrals to over several hundred clients
- > Received recognition for autism research program as one of the top 10 advances in the field of autism

## 2008

- > Branded the growing company as 'Medical Neurogenetics, LLC' to establish the company's focus on neurogenetic disease

## 2001



